247 related articles for article (PubMed ID: 30224193)
1. Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment.
Sahasrabudhe V; Terra SG; Hickman A; Saur D; Raje S; Shi H; Matschke K; Zhou S; Cutler DL
Clin Ther; 2018 Oct; 40(10):1701-1710. PubMed ID: 30224193
[TBL] [Abstract][Full Text] [Related]
2. Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor.
Fediuk DJ; Nucci G; Dawra VK; Cutler DL; Amin NB; Terra SG; Boyd RA; Krishna R; Sahasrabudhe V
Clin Pharmacokinet; 2020 Aug; 59(8):949-965. PubMed ID: 32337660
[TBL] [Abstract][Full Text] [Related]
3. Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects.
Dawra VK; Sahasrabudhe V; Liang Y; Matschke K; Shi H; Hickman A; Saur D; Terra SG; Cutler DL
Clin Ther; 2018 Sep; 40(9):1538-1547. PubMed ID: 30170758
[TBL] [Abstract][Full Text] [Related]
4. A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects
.
Dawra VK; Liang Y; Shi H; Bass A; Hickman A; Terra SG; Zhou S; Cutler D; Sahasrabudhe V
Int J Clin Pharmacol Ther; 2019 Apr; 57(4):207-216. PubMed ID: 30802200
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus.
Sahasrabudhe V; Terra SG; Hickman A; Saur D; Shi H; O'Gorman M; Zhou Z; Cutler DL
J Clin Pharmacol; 2017 Nov; 57(11):1432-1443. PubMed ID: 28703316
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic Properties of Single and Multiple Doses of Ertugliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects.
Li Y; Mu Y; Shi H; Liang Y; Liu Z; Matschke K; Hickman A; Krishna R; Sahasrabudhe V
Clin Pharmacol Drug Dev; 2020 Jan; 9(1):97-106. PubMed ID: 30934166
[TBL] [Abstract][Full Text] [Related]
7. Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.
Urva S; Quinlan T; Landry J; Ma X; Martin JA; Benson CT
Clin Pharmacokinet; 2022 Jul; 61(7):1057-1067. PubMed ID: 35674880
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects.
Li Y; Nucci G; Yamamoto Y; Fediuk DJ; Sahasrabudhe V
Clin Pharmacol Drug Dev; 2021 Jul; 10(7):765-776. PubMed ID: 33434408
[TBL] [Abstract][Full Text] [Related]
9. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
[TBL] [Abstract][Full Text] [Related]
10. Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin.
Raje S; Callegari E; Sahasrabudhe V; Vaz A; Shi H; Fluhler E; Woolf EJ; Schildknegt K; Matschke K; Alvey C; Zhou S; Papadopoulos D; Fountaine R; Saur D; Terra SG; Stevens L; Gaunt D; Cutler DL
Clin Transl Sci; 2018 Jul; 11(4):405-411. PubMed ID: 29575530
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetic Model for Ertugliflozin in Healthy Subjects and Patients With Type 2 Diabetes Mellitus.
Fediuk DJ; Zhou S; Dawra VK; Sahasrabudhe V; Sweeney K
Clin Pharmacol Drug Dev; 2021 Jul; 10(7):696-706. PubMed ID: 33205593
[TBL] [Abstract][Full Text] [Related]
12. Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning.
Nakamaru Y; Kakubari M; Yoshida K; Akimoto M; Todorovic V; Greis T; Kondo K
Clin Ther; 2020 Aug; 42(8):1467-1482.e4. PubMed ID: 32800532
[TBL] [Abstract][Full Text] [Related]
13. Bioequivalence of Metformin in Ertugliflozin/Metformin Fixed-Dose Combination Tablets to Canadian-Sourced Metformin Coadministered With Ertugliflozin Under Fasted and Fed States.
Dawra VK; Pelletier K; Matschke K; Shi H; Hickman A; Zhou S; Krishna R; Sahasrabudhe V
Clin Pharmacol Drug Dev; 2021 May; 10(5):510-520. PubMed ID: 33135865
[TBL] [Abstract][Full Text] [Related]
14. Relative bioavailability of ertugliflozin tablets containing the amorphous form versus tablets containing the cocrystal form.
Sahasrabudhe V; Matschke K; Shi H; Hickman A; Kong A; Rodríguez Spong B; Nickerson B; Arora KK
Int J Clin Pharmacol Ther; 2022 Jul; 60(7):317-326. PubMed ID: 35575420
[TBL] [Abstract][Full Text] [Related]
15. No apparent pharmacokinetic interactions were found between henagliflozin: A novel sodium-glucose co-transporter 2 inhibitor and glimepiride in healthy Chinese male subjects.
Que L; Huang K; Xiang X; Ding Y; Chu N; He Q
J Clin Pharm Ther; 2022 Aug; 47(8):1225-1231. PubMed ID: 35362180
[TBL] [Abstract][Full Text] [Related]
16. Meta-Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure.
Marshall JC; Liang Y; Sahasrabudhe V; Tensfeldt T; Fediuk DJ; Zhou S; Krishna R; Dawra VK; Wood LS; Sweeney K
J Clin Pharmacol; 2021 Sep; 61(9):1220-1231. PubMed ID: 33813736
[TBL] [Abstract][Full Text] [Related]
17. Ertugliflozin as a monotherapy for the treatment of type 2 diabetes.
Hu J; Deng A; Zhao Y
Expert Opin Pharmacother; 2018 Nov; 19(16):1841-1847. PubMed ID: 30223693
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations.
Fediuk DJ; Sahasrabudhe V; Dawra VK; Zhou S; Sweeney K
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1297-1306. PubMed ID: 34213819
[TBL] [Abstract][Full Text] [Related]
19. Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study.
Peveling-Oberhag J; Zeuzem S; Yong WP; Kunz T; Paquet T; Bouillaud E; Urva S; Anak O; Sellami D; Kobalava Z
Clin Ther; 2013 Mar; 35(3):215-25. PubMed ID: 23453404
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of Rolapitant in Patients With Mild to Moderate Hepatic Impairment.
Wang J; Wang X; Zhang ZY; Arora S; Lu S; Kansra V
J Clin Pharmacol; 2018 May; 58(5):686-693. PubMed ID: 29329482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
